1 active not recruiting, 1 recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 1, Recruiting 1 |
Follow NTLA-2001: new trials by email Literature Review of NTLA-2001 trials Research Report on NTLA-2001
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Study of NTLA-2001 in ATTRv-PN nexiguran ziclumeran, Normal Saline as Placebo - Neuromuscular Disease, Neuromuscular Diseases (NMD) | Phase 3 | Active not recruiting | Intellia Therapeutics | 67 | 2024-11-22 | 2026-11-05 |
| MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) NTLA-2001, Placebo - Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | Phase 3 | Recruiting | Intellia Therapeutics | 1200 | 2023-12-13 | 2026-11-04 |
Amyloidosis (2) · Amyloidosis, Familial (2) · Amyloidosis, Hereditary, Transthyretin-Related (2) · Amyloid Neuropathies (1) · Amyloid Neuropathies, Familial (1) · Cardiomyopathies (1) · Genetic Diseases, Inborn (1) · Heredodegenerative Disorders, Nervous System (1) · Metabolic Diseases (1) · Metabolism, Inborn Errors (1) · Nervous System Diseases (1) · Neurodegenerative Diseases (1) · Neuromuscular Diseases (1) · Peripheral Nervous System Diseases (1) · Polyneuropathies (1)
Argentina (2) · Brazil (2) · Mexico (2) · Singapore (2) · Taiwan (2) · Australia (1) · Austria (1) · Belgium (1) · Canada (1) · Czechia (1) · Denmark (1) · France (1) · Germany (1) · Hungary (1) · Israel (1)